Search

Your search keyword '"Alshak, Mark"' showing total 42 results
Start Over Author "Alshak, Mark"
42 results on '"Alshak, Mark"'

3. Safety and Effectiveness of Urologist-Directed Extracorporeal Shock Wave Lithotripsy for Pancreatolithiasis.

Author

Alam, Ridwan, Bhanji, Yasin, Alshak, Mark N., Rabinowitz, Matthew J., Li, Oscar, Joice, Gregory A., Patel, Hiten D., Winoker, Jared S., and Matlaga, Brian R.

Subjects
EXTRACORPOREAL shock wave lithotripsy, ENDOSCOPIC retrograde cholangiopancreatography, OPIOID analgesics, JOINT ventures, LOGISTIC regression analysis
Abstract

Introduction: Extracorporeal shock wave lithotripsy (SWL) can be used in conjunction with endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of large (≥5 mm) or impacted pancreatolithiasis. We report our experience demonstrating the safety and effectiveness of urologist-directed SWL for pancreatolithiasis. Methods: We performed a retrospective review of all patients undergoing SWL for pancreatolithiasis at our institution between 2016 and 2020. We defined a treatment cycle as one in which the patient underwent a predefined number of SWL procedures prior to performance of a post-SWL ERCP. Stone-free status was defined as the absence of stone fragments at post-SWL ERCP. Multivariable logistic regression was performed to determine characteristics associated with stone persistence after a treatment cycle. Results: There were 44 patients who underwent 59 treatment cycles consisting of 118 pancreatic SWL procedures. Forty-two cycles (71.2%) were staged, and 17 (28.8%) were not staged. The median size of the largest pancreatic stone was 9 mm [IQR 6–11] and was impacted in 38 cases (64.4%). Patients reported pain in 51 cases (86.4%), of which 28 required the use of opioid analgesics. Patients were rendered stone free in 38 cycles (64.4%). Pain improvement was noted in 39 cases (66.1%), and the reduction in opioid use was statistically significant (28 cases vs. 10 cases, P = 0.004). Impacted stones were associated with an increased odds of stone persistence (OR 7.04, 95% CI 1.14–43.43, P = 0.04). Conclusions: In this joint venture with gastroenterology, we demonstrate that urologist-directed SWL for pancreatolithiasis is safe, effective, and in line with published rates. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection

Author

Kingery, Justin R., Safford, Monika M., Martin, Paul, Lau, Jennifer D., Rajan, Mangala, Wehmeyer, Graham T., Li, Han A., Alshak, Mark N., Jabri, Assem, Kofman, Alina, Babu, Christopher S., Benitez, Elizabeth K., Palacardo, Federico, Das, Indrani Guzman, Kaylor, Kiara, Woo, Kwang M., Roberts, Nicholas L., Rahiel, Saher, Gali, Varshini, Han, Lynn, Lee, Joyce, Roszkowska, Natalia, Kim, Yeo Eun, Bakshi, Sufia, Hogan, Cameron, McNairy, Margaret, Pinheiro, Laura C., and Goyal, Parag

Published
2022
Full Text
View/download PDF

8. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial

Author

Chughtai, Bilal, Elterman, Dean, Shore, Neal, Gittleman, Marc, Motola, Jay, Pike, Sheldon, Hermann, Craig, Terrens, William, Kohan, Alfred, Gonzalez, Ricardo R., Katz, Aaron, Schiff, Jeffery, Goldfischer, Evan, Grunberger, Ivan, Tu, Le Mai, Alshak, Mark N., and Kaminetzky, Jed

Published
2021
Full Text
View/download PDF

9. Thirty-Day Post-Discharge Outcomes Following COVID-19 Infection

Author

Kingery, Justin R., BF Martin, Paul, Baer, Ben R., Pinheiro, Laura C., Rajan, Mangala, Clermont, Adrienne, Pan, Sabrina, Nguyen, Khoi, Fahoum, Khalid, Wehmeyer, Graham T., Alshak, Mark N., Li, Han A., Choi, Justin J., Shapiro, Martin F., McNairy, Margaret L., Safford, Monika M., and Goyal, Parag

Published
2021
Full Text
View/download PDF

22. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device

Author

Elterman, Dean, primary, Alshak, Mark N., additional, Martinez Diaz, Susana, additional, Shore, Neal, additional, Gittleman, Marc, additional, Motola, Jay, additional, Pike, Sheldon, additional, Hermann, Craig, additional, Terens, William, additional, Kohan, Alfred, additional, Gonzalez, Ricardo, additional, Katz, Aaron, additional, Schiff, Jeffrey, additional, Goldfischer, Evan, additional, Grunberger, Ivan, additional, Tu, Le, additional, Kaminetsky, Jed, additional, and Chughtai, Bilal, additional

Published
2023
Full Text
View/download PDF

24. Comparing risk of post infection erectile dysfunction following SARS Coronavirus 2 stratified by acute and long COVID, hospitalization status, and vasopressor administration: a U.S. large claims database analysis

Author

Grutman, Aurora J., Gilliam, Kelli, Maremanda, Ankith P., Able, Corey, Choi, Una, Alshak, Mark N., and Kohn, Taylor P.

Abstract

No study has yet assessed the risk of developing erectile dysfunction (ED) after a diagnosis of long COVID, defined by the Centers for Disease Control and Prevention as the persistence or presence of new symptoms at least 4 weeks after initial SARS-CoV-2 infection, when compared to those diagnosed with acute COVID or cases in which more severe treatment is required. To assess these risks, we queried the TriNetX COVID-19 Research Network from December 1st 2020 through June 2023. Men aged ≥ 18 diagnosed with long COVID were compared to those diagnosed with acute COVID and analyses were performed to compare men who were/were not hospitalized within 1 month of acute COVID diagnosis and men who did/did not need vasopressors. Cohorts were propensity score matched and compared for differences in new ED diagnosis and/or prescription of phosphodiesterase-5 inhibitors (PDE5i). After propensity score matching, the long and acute COVID cohorts included 2839 men with an average age of 54.5±16.7 and 55.1±17.1 years respectively (p= 0.21). Men with long COVID were more likely to develop ED or be prescribed PDE5i (3.63%) when compared to men with only acute COVID infections (2.61%) [RR 1.39; 95% CI 1.04, 1.87]. There was no statistically significant risk of developing ED or being prescribed PDE5i for individuals who received vasopressors [RR 0.92; 95% CI 0.77,1.10] or were hospitalized [RR 0.93; 95% CI 0.82,1.06].

Published
2024
Full Text
View/download PDF

25. MP09-01 THE ROLE OF PROPHYLACTIC ANTIBIOTICS IN TRANSPERINEAL PROSTATE BIOPSY: A SYSTEMATIC REVIEW AND METANALYSIS

Author

Basourakos, Spyridon, primary, Alshak, Mark, additional, Lewicki, Patrick, additional, Cheng, Emily, additional, Tzeng, Michael, additional, DeRosa, Antonio, additional, Allaway, Matthew, additional, Ross, Ashley, additional, Schaeffer, Edward, additional, Patel, Hiten, additional, Hu, Jim, additional, and Gorin, Michael, additional

Published
2022
Full Text
View/download PDF

26. MP01-06 PRESERVATION OF EJACULATORY AND ERECTILE FUNCTION WITH ITIND SYSTEM FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA

Author

Chughtai, Bilal, primary, Kaminetsky, Jed, additional, Shore, Neal, additional, Gittleman, Marc, additional, Motola, Jay, additional, Pike, Sheldon, additional, Herman, Craig, additional, Terens, William, additional, Kohan, Alfred, additional, Gonzalez, Ricardo, additional, Katz, Aaron, additional, Schiff, Jeffrey, additional, Goldfischer, Evan, additional, Grunberger, Ivan, additional, Tu, Le Mai, additional, Alshak, Mark, additional, and Elterman, Dean, additional

Published
2021
Full Text
View/download PDF

27. PD18-10 THE ITIND TEMPORARILY IMPLANTED NITINOL DEVICE FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA: A MULTICENTER, RANDOMIZED, CONTROLLED TRIAL

Author

Chughtai, Bilal, primary, Elterman, Dean, additional, Shore, Neal, additional, Gittleman, Marc, additional, Motola, Jay, additional, Pike, Sheldon, additional, Herman, Craig, additional, Terens, William, additional, Kohan, Alfred, additional, Gonzalez, Ricardo, additional, Katz, Aaron, additional, Schiff, Jeffrey, additional, Goldfischer, Evan, additional, Grunberger, Ivan, additional, Tu, Le Mai, additional, Alshak, Mark, additional, and Kaminetsky, Jed, additional

Published
2021
Full Text
View/download PDF

31. Obesity and COVID-19 in New York City: A Retrospective Cohort Study

Author

Goyal, Parag, primary, Ringel, Joanna Bryan, additional, Rajan, Mangala, additional, Choi, Justin J., additional, Pinheiro, Laura C., additional, Li, Han A., additional, Wehmeyer, Graham T., additional, Alshak, Mark N., additional, Jabri, Assem, additional, Schenck, Edward J., additional, Chen, Ruijun, additional, Satlin, Michael J., additional, Campion, Thomas R., additional, Nahid, Musarrat, additional, Plataki, Maria, additional, Hoffman, Katherine L., additional, Reshetnyak, Evgeniya, additional, Hupert, Nathaniel, additional, Horn, Evelyn M., additional, Martinez, Fernando J., additional, Gulick, Roy M., additional, and Safford, Monika M., additional

Published
2020
Full Text
View/download PDF

32. Clinical Characteristics of Covid-19 in New York City

Author

Goyal, Parag, primary, Choi, Justin J., additional, Pinheiro, Laura C., additional, Schenck, Edward J., additional, Chen, Ruijun, additional, Jabri, Assem, additional, Satlin, Michael J., additional, Campion, Thomas R., additional, Nahid, Musarrat, additional, Ringel, Joanna B., additional, Hoffman, Katherine L., additional, Alshak, Mark N., additional, Li, Han A., additional, Wehmeyer, Graham T., additional, Rajan, Mangala, additional, Reshetnyak, Evgeniya, additional, Hupert, Nathaniel, additional, Horn, Evelyn M., additional, Martinez, Fernando J., additional, Gulick, Roy M., additional, and Safford, Monika M., additional

Published
2020
Full Text
View/download PDF

33. AUTHOR REPLY

Author

Alshak, Mark N., primary, Patel, Neal, additional, and Hu, Jim C., additional

Published
2020
Full Text
View/download PDF

34. Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series

Author

van der Mijn, Johannes C., primary, Al Hussein Al Awamlh, Bashir, additional, Islam Khan, Aleem, additional, Posada-Calderon, Lina, additional, Oromendia, Clara, additional, Fainberg, Jonathan, additional, Alshak, Mark, additional, Elahjji, Rahmi, additional, Pierce, Hudson, additional, Taylor, Benjamin, additional, Gudas, Lorraine J., additional, Nanus, David M., additional, Molina, Ana M., additional, Del Pizzo, Joseph, additional, and Scherr, Douglas S., additional

Published
2019
Full Text
View/download PDF

41. Neuroanatomy, Sympathetic Nervous System

Author

Alshak MN and M Das J

Abstract

The sympathetic nervous system (SNS) is one of the two divisions of the autonomic nervous system (ANS), along with the parasympathetic nervous system (PNS), These systems primarily work unconsciously in opposite ways to regulate many functions and parts of the body. Colloquially, the SNS governs the "fight or flight" response while the PNS controls the "rest and digest" response. The main overall end effect of the SNS is to prepare the body for physical activity, a whole-body reaction affecting many organ systems throughout the body to redirect oxygen-rich blood to areas of the body needed during intense physical demand.[1], (Copyright © 2022, StatPearls Publishing LLC.)

Published
2022

42. Prostatic urethral lift (UroLift) versus convective water vapor ablation (Rezum) for minimally invasive treatment of BPH: a comparison of improvements and durability in 3-year clinical outcomes.

Author

Elterman D, Shepherd S, Saadat SH, Alshak MN, Bhojani N, Zorn KC, Rijo E, Misrai V, Lajkosz K, and Chughtai B

Subjects
Humans, Male, Middle Aged, Minimally Invasive Surgical Procedures methods, Prostate surgery, Quality of Life, Steam, Treatment Outcome, Lower Urinary Tract Symptoms etiology, Lower Urinary Tract Symptoms surgery, Prostatic Hyperplasia complications, Prostatic Hyperplasia surgery
Abstract

Introduction: Half of men aged > 60 years will develop benign prostatic hyperplasia (BPH) with 40% of these men having moderate-to-severe lower urinary tract symptoms (LUTS). There is limited knowledge on a head-to-head comparison of prostatic urethral lift (UroLift) and convective water vapor ablation (Rezum) for the treatment of LUTS secondary to BPH. We sought to compare randomized controlled trials with 3-year clinical outcome data., Materials and Methods: After a thorough literature search, two multicenter sham-controlled double-blind randomized trials for UroLift and Rezum were identified and compared. Both studies had similar designs, baseline characteristics, reported outcomes, and low risks of bias., Results: Rezum and UroLift resulted in significant improvement of International Prostate Symptom Score (IPSS) at 3 months (51.4% and 49.9%, respectively) and 50% reduction of IPSS Quality of Life that was durable across all time points. At 24 and 36 months, there was a statistically significant difference in IPSS between groups, favoring Rezum (-11.2 ± 7.3 versus -9.13 ± 7.62, p = 0.04, and -11.0 ± 7.1 versus -8.83 ± 7.41, p = 0.04, respectively). While Rezum had greater improvement in Qmax at 3 months (6.4 ± 7.2 versus 4.29 ± 5.16, p < 0.01), there was no difference in improvement from 12-36 months between treatments. Only UroLift experienced improvements of Men's Sexual Health Questionnaire- Ejaculatory Dysfunction (MSHQ-EjD) function from baseline and was better than Rezum at all time points (p < 0.01). Rezum failed to significantly reduce the MSHQ-EjD bother at 3 months, while UroLift demonstrated a significant reduction of 27.56% (p < 0.01). Both systems offered equal improvements in the bother score by 12-36 months. Surgical re-treatment rates favored Rezum over Urolift (4.4% vs. 10.7%, respectively)., Conclusions: Rezum achieved a greater improvement in symptom relief compared to UroLift. Improvement in ejaculatory dysfunction in patients treated with UroLift was greater than Rezum.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results